SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. )*
CYTOCLONAL PHARMACEUTICS
________________________________________________________________________
(Name of Issuer)
Common Stock
________________________________________________________________________
(Title of Class of Securities)
23282G105
________________________________________________________________________
(CUSIP Number)
Paul F. Byrne c/o Janssen-Meyers Associates, L.P. 17 State Street,
NY, NY 10004
(212) 742-4200
________________________________________________________________________
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and
Communications)
11/2/95
________________________________________________________________________
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement
on Schedule 13G to report the acquisition which is the
subject of this Schedule 13D, and is filing this schedule
because of Rule 13d-1(b)(3) or (4), check the
following box_____.
Check the following box if a fee is being paid with
the statement _____. (A fee is not required only if the
reporting person: (1) has a previous statement on file
reporting beneficial ownership of more than five
percent of the class of securities described in Item1;
and (2) has filed no amendment subsequent thereto
reporting beneficial ownership of five percent of less
of such class.) (Sec Rule 13d-7.)
Note: Six copies of this statement, including all exhibits,
should be filed with the Commission. See Rule
13d-1(a) for other parties to whom copies are to be sent.
*The remainder of this cover page shall be filled out
for a reporting person's initial filing on this form with
respect to the subject class of securities, and for
any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover
page shall not be deemed to be "filed" for the
purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities
of that section of the Act but shall be subject to all
other provisions of the Act (however, see the Notes).
1. Name of Reporting Person
Janssen-Meyers Associates, L.P.
_____________________________________________________
S.S. or I.R.S. Identification No. of Above Person
_____________________________________________________
2. Check the Appropriate Box if a Member of a Group
(See Instructions before filling out)
a.________ b_____X__
3. SEC USE ONLY
_____________________________________________________
4. Source of Funds (See instructions before filling out).
______________________________________________________
5. Check Box if Disclosure of Legal Proceedings is
Required Pursuant to Items
2(d) or 2(e).
_____________________________________________________________________________
6. Citizenship or Place of Organization
USA NY Limited Partnership
____________________________________________________
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
(Questions 7 - 10)
7. Sole Voting Power
1,689,500 shares Common Stock
____________________________________________________
8. Shared Voting Power
_____________________________________________________
9. Sole Dispositive Power
1,689,500 shares Common Stock
_____________________________________________________
10. Shared Dispositive Power
_____________________________________________________
11. Aggregate Amount Beneficially Owned by Each
Reporting Person
1,689,500 shares Common Stock
_____________________________________________________
12. Check Box if the Aggregate Amount in Row (11)
Excludes Certain Shares
(See instructions before filling out)
NA
_____________________________________________________
13. Percent of Class Represented by Amount in Row (11)
22.8%
______________________________________________________
14. Type of Reporting Person (See instructions
before filling out)
BD/PN
______________________________________________________
